Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension

Journal of Hypertension

Volumn 17, Issue 7, 1999, Pages 873-881

  Birkenhäger, Willem H ^a   De Leeuw, Peter W ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ACE inhibition; Angiotensin; Angiotensin receptor antagonist; Hypertension

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN HEXETIL; IRBESARTAN; LOSARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

AMBULATORY MONITORING; BLOOD PRESSURE MONITORING; DRUG EFFICACY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MICROALBUMINURIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT;

EID: 0033035229     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917070-00002     Document Type: Review

References (85)

1. 1 Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharacol Sci 1991; 12:55-62.
2. 2 Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharamacol Rev 1993; 45:205-251.
3. 3 Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127:1388-1401.
4. 4 Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334:1649-1654.
5. 5 Griendling KK, Lassègue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996; 36:281-306.
6. 6 McInnes G. Pocket reference to angiotensin II antagonists. London: Science Press Ltd; 1997.
7. 7 Johnston CI, Naitoh M, Burrell LM. Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues. J Hypertens 1997; 15 (suppl 7):S3-S6.
8. 8 McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74:181-194.
9. 9 Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 1998; 16 (suppl 7):S3-S9.
10. 10 Lin SY, Goodfriend TL. Angiotensin receptors. Am J Physiol 1970; 218:1319-1328.
11. 11 Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351:233-236.
12. 12 Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993; 268:24539-24542.
13. 13 Koike G, Horiuchi M, Yamada T, Szpirer C, Jacob HJ, Dzau VJ. Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun 1994; 203:1842-1850.
14. 14 Leung KH, Smith RD, Timmermans PBMWM, Chiu AT. Regional distribution of the two subtypes of angiotensin II receptor in rat brain using selective nonpeptide antagonists. Neurosci Lett 1991; 123:95-98.
15. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100:264-269.
16. 16 Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651-657.
17. 1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92:10663-10667.
18. 18 Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996; 28:397-402.
19. 2 receptors. High Blood Pressure Cardiovasc Prev 1998; 7:51-57.
20. 20 Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98:418-425.
21. 21 Inoue Y, Nakamura N, Inagami T. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens 1997; 15:703-714.
22. 22 Wong PC, Timmermans PBMWM. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. J Pharmacol Exp Ther 1991; 258:49-57.
23. 23 Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1 H-benzidamole-7-carboxylic acid (CV-11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1 H-benzidamole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266:114-120.
24. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265:826-834.
25. 1 antagonism. J Pharmacol Exp Ther 1995; 273:753-761.
26. 1 receptor. Eur J Pharmacol 1997; 319:137-146.
27. 27 Morsing P, Brandt-Eliasson U, Abrahamsson T. Candesartan, an insurmountable antagonist of angiotensin II mediated contractile effects in isolated vascular preparations: a comparison with irbesartan, losartan and its active metabolite (EXP 3174) [Abstract]. Am J Hypertens 1998; 11:37A.
28. 28 Abrahamsson T, Brandt-Eliasson U, Morsing P, Sjöquist P-O. Candesartan causes a long-lasting antagonism of the angiotensin II receptor mediated contractile effects in isolated vascular preparations: a comparison with losartan and its active metabolite (EXP 3174) [Abstract]. Am J Hypertens 1998; 11:36A.
29. 29 Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PBMWM, Brunner HR. Dose-response relationships following oral administration of DUP 753 to normal humans. Am J Hypertens 1991; 4:350S-354S.
30. 1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan. J Biol Chem 1994; 269:16533-16536.
31. 31 Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. Am J Hypertens 1992; 5:247S-251S.
32. 32 Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25:37-46.
33. 33 Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75:793-795.
34. 34 Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155:405-411.
35. 35 Mallion J-M, Bradstreet DC, Makris L, Goldberg AI, Halasz S, Sweet CS, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens 1995; 13 (suppl 1):S35-S41.
36. 36 Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25:1345-1350.
37. 37 Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J. Efficacy, tolerablity, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18:608-625.
38. 38 Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Pressure 1997; 6:35-43.
39. 39 Ramsay LE, Yeo WW, on behalf of the Losartan Cough Study Group. Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough. J Hypertens 1995; 13 (suppl 1):S73-S76.
40. 40 Van Rijnsoever EW, Kwee-Zuiderwijk WJM, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158:2063-2065.
41. 41 Mackay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med 1996; 156:278-285.
42. 42 Nakashima M, Uematsu T, Kosage K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42:333-335.
43. 43 Azizi M, Guyene T-T, Chatellier G, Wargon M, Ménard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29:634-640.
44. 44 Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997; 11 (suppl 2):S9-S17.
45. 45 Sever P, Holzgrevo H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (suppl 2):S69-S73.
46. 46 Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1998; 82:961-965.
47. 47 McInnes GT, O'Kane KPJ, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (suppl 2):S75-S80.
48. 48 Heuer HJ, Schöndorfer G, Högemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (suppl 2):S55-S56.
49. 49 Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (suppl 2):S63-S64.
50. 50 Zanchetti A. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents. J Hypertens 1997; 15 (suppl 7):S21-S25.
51. 51 Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16:1685-1691.
52. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25:22-29.
53. 53 Man in 't Veld AJ. Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J Hypertens 1997; 15 (suppl 7):S27-S33.
54. 54 Ruilope L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. J Hypertens 1997; 11 (suppl 7):S15-S20.
55. 55 Pouleur HG. Clinical overview of irbesartan. A new angiotensin II receptor antagonist. Am J Hypertens 1997; 10:318S-324S.
56. 56 Simon TA, Gelarden RT, Freitag SA, Kassler-Taub KB, Davies R. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998; 82:179-182.
57. 57 Waeber B, Brunner HR. A look through the new therapeutic window: irbesartan. J Hypertens 1998; 16 (suppl 7):S11-S16.
58. 58 Stumpe KO, Haworth D, Hoglund C, Kerwin L, Martin A, Simon T, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Pressure 1998; 7:31-37.
59. 59 Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, Triscari J, et al. An elective-titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther 1998; 20:398-409.
60. 60 Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E, for the Irbesartan/ Losartan Study investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998; 11:445-453.
61. 61 Markham A, Goa KL, Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54:299-311.
62. 62 Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18:797-810.
63. 63 Neutel J, Weber M, Pool J, Smith D, Fitzsimmons S, Chiang YT, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19:447-458.
64. 64 Hegner G, Faust G, Freytag F, Meilenbrock S, Sullivan J, Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997; 52:173-177.
65. 65 Cifkova R, Peleska J, Hradec J, Rosolova H, Pinterova E, Zeman K, et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998; 12:563-567.
66. 66 Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042.
67. 67 Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60:341-346.
68. 68 Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14:1147-1151.
69. 69 Black HR, Graff A, Shute D, Stolz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997; 11:483-489.
70. 70 Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997; 19:1263-1285.
71. 71 Rongen GA, Brooks SC, Ando S, Dajani HR, Abramson BL, Floras JS. Neural and hypotensive effects of angiotensin II receptor blockade. Hypertension 1998; 31:378-383.
72. 72 Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22:339-347.
73. 73 Fridman K, Anderson OK, Wysocki M, Friberg P. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodyriamics in hypertensive patients. J Hum Hypertens 1997; 11 (suppl 2):S43-S44.
74. 74 Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac S, Brouard R, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25:602-609.
75. 75 Doig JK, Macfadyen RJ, Sweet CS, Reid JL. Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol 1995; 25:511-517.
76. 76 Price DA, De'Oliveira JM, Fischer NDL, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healhy men. Hypertension 1997; 30:240-246.
77. 77 Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, et al. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1998; 16:385-393.
78. 78 Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 (suppl 2):19-22.
79. 79 Gansevoort RT, De Zeeuw D, Shahinfar S, Redfield A, De Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 (suppl 2):S37-S42.
80. 80 Nunez E, Hosoya K, Susic D, Frohlich ED. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997; 29:519-524.
81. 81 Himmelmann A, Svensson A, Bergbrant A, Hansson L. Long-term effects of losartan on blood pressure and left ventricular structure in hypertension. J Hum Hypertens 1996; 10:729-734.
82. 82 Cheung B. Increased left-ventricular mass after losartan treatment. Lancet 1997; 349:1743-1744.
83. 83 Cuspidi C, Lonati L, Sampieri L, Valagussa L, Macca C, Leonetti G, et al. Effects of losartan on blood pressure and left ventricular mass in essential hypertension. High Blood Pressure Cardiovasc Prev 1998; 7:75-79.
84. 84 Dahlöf B, Devereux R, De Faire U, Fyhrquist F, Hedner T, Ibsen H, et al., for the LIFE study group. The Losartan Intervention for Endpoint Reduction (LIFE) in Hypertension Study. Rationale, design, and methods. Am J Hypertens 1997; 10:705-713.
85. 85 Mann J, Julius S, for the VALUE Trial Group. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998; 7:176-183.